BioSpace News Archive

Amgen announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD) today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”) has been merged with and into Ironwood Pharmaceuticals GmbH (“Merger Sub”), a wholly-owned subsidiary of Ironwood organized under the laws of Switzerland.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers.

Champions Oncology, Inc., a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its financial results for its second quarter of fiscal 2024, ended October 31, 2023.

Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 1:30 p.m. Pacific Time.

Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live bacteria capsule (Lc262-1) has successfully met its primary and secondary endpoints.

Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) today announced that it has entered into a joint research agreement with JCR Pharmaceuticals Co., Ltd. (JCR Pharmaceuticals) on joint evaluation of the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target.

Clover Biopharmaceuticals, Ltd. today announced that enrollment of the first participants has been completed in a Phase Ⅰ first-in-human study evaluating the company’s RSV PreF-Trimer subunit vaccine candidate (SCB-1019), which is based on Clover’s Trimer-Tag vaccine technology platform.

Zai Lab Limited announced that the 2023 National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include the following medicines and indications.